WorldCat Linked Data Explorer

Turtle N-Triple JSON-LD RDF/XML HTML Contact Us Home

http://worldcat.org/entity/work/id/1057266878

Systems biology in biotech & pharma : a changing paradigm

The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this technology. Many educational institutions (particularly their med.

Open All Close All

type

about

http://schema.org/about

alternateName

http://schema.org/alternateName

  • "Systems biology in biotech and pharma"
  • "Systems biology in biotech and pharma"@en

contributor

creator

description

http://schema.org/description

  • "The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this technology. Many educational institutions (particularly their med."@en
  • "Annotation. The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development.This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this technology. Many educational institutions (particularly their medical divisions) at present are heavily business-oriented, realize that in this particular industrial environment, that every dollar counts."
  • "Systems Biology (SB) is a suite of technologies and methodologies that resulted, conceptually from the merging of two basic paradigms, reductionism and holism. It represents a combination of reductionist and holistic approaches to the relationships among the elements of a system, with the goal of identifying its emergent properties and defining, quantitatively, molecular, cellular, tissue, organ and whole body processes. One manifestation of SB is as a tool for hypothesis generation about a system that is typically too large and complex to understand by simple reasoning."

genre

http://schema.org/genre

  • "Electronic books"
  • "Electronic books"@en

name

http://schema.org/name

  • "Systems biology in biotech & pharma : a changing paradigm"@en
  • "Systems biology in biotech & pharma : a changing paradigm"
  • "Systems biology in biotech and pharma : a changing paradigm"
  • "Systems Biology in Biotech & Pharma a Changing Paradigm"@en
  • "Systems biology in biotech & pharma a changing paradigm"@en
  • "Systems biology in biotech & pharma a changing paradigm"
  • "Systems Biology in Biotech & Pharma A Changing Paradigm"

workExample